Diane Chan is a Neurology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
55 Fruit Street
Wacc 720
Boston, MA 02114
Telephone
617-726-5523Registry record last updated 20 Jun 2019.
Clinical trials
- Gamma Light and Sound Stimulation to Prevent Dementia in Cognitively Normal People at Risk for Alzheimer's Disease
Sponsor: Massachusetts General Hospital
- Daily Light and Sound Stimulation to Improve Brain Functions in Alzheimer's Disease
Sponsor: Massachusetts Institute of Technology
- High Frequency Light and Sound Stimulation to Improve Brain Functions in Alzheimer's Disease
Sponsor: Massachusetts Institute of Technology
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
91.4%Aromatic Amino Acid Decarboxylation Inhibitor27.9%Carbidopa-Levodopa75%Carbidopa-Levodopa Er25%Part D≥49 patientsCholinesterase Inhibitor18.3%Donepezil Hcl69%Rivastigmine31%Part D<11 patients+ 10 more classes in this area
Cardiovascular
7.2%Beta blocker7.2%Propranolol Hcl Er51%Propranolol Hcl49%Part D≥12 patientsMusculoskeletal
1.4%Central alpha-2 Adrenergic Agonist1.4%Tizanidine Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2010–2012 per NIH RePORTER. The latest:
- LRRK2 and RhoGTPases: Local translation in neurodegeneration
Boston University Medical Campus
FY2012$31,945F30NS066658 - LRRK2 and RhoGTPases: Local translation in neurodegeneration
Boston University Medical Campus
FY2011$46,800F30NS066658 - LRRK2 and RhoGTPases: Local translation in neurodegeneration
Boston University Medical Campus
FY2010$46,380F30NS066658
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”